

INDGN/SE/2024-25/22

August 1, 2024

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	--

Dear Sir / Madam,

**Sub: Intimation of outcome of Board Meeting**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Indegene Limited at its meeting held today, i.e., August 1, 2024, has approved the following:

Unaudited Standalone and Consolidated Financial Results along with limited review report of the Auditors thereon for the quarter June 30, 2024. The Financial Results along with the limited review report of the Auditors with an unmodified opinion are attached herewith.

The meeting of the Board of Directors commenced at 6:34 p.m. and concluded at 7:22 p.m.

The above information is being made available on the website of the Company.

<https://www.indegene.com/>

This is for your information and records.

Yours Sincerely,

**For Indegene Limited**  
**(Formerly known as Indegene Private Limited)**

**Srishti Ramesh Kaushik**  
**Company Secretary and Compliance officer**



Indegene Limited (Formerly Indegene Private Limited),  
Third Floor, Aspen G-4 Block, Manyata Embassy  
Business Park (SEZ), Outer Ring Road, Nagawara,  
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777  
[www.indegene.com](http://www.indegene.com)

CIN: U73100KA1998PLC102040

**Limited Review Report on unaudited consolidated financial results of Indegene Limited (formerly known as Indegene Private Limited) for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Indegene Limited (formerly known as Indegene Private Limited)**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Indegene Limited (formerly known as Indegene Private Limited) (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the audited year to date figures up to the third quarter of the previous financial year.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**Limited Review Report (Continued)**

**Indegene Limited (formerly known as Indegene Private Limited)**

7. We did not review the interim financial information of 5 step subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 1,160 million, total net profit after tax (before consolidation adjustments) of Rs. 78 million and total comprehensive income (before consolidation adjustments) of Rs. 86 million, for the quarter ended 30 June 2024, as considered in the Statement. The interim financial information of these step subsidiaries have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of 3 subsidiaries and 5 step subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 236 million, total net profit after tax (before consolidation adjustments) of Rs. 1 million and total comprehensive loss (before consolidation adjustments) of Rs. 19 million, for the quarter ended 30 June 2024, as considered in the Statement. According to the information and explanations given to us by the Parent's management, the interim financial information of these subsidiaries and step subsidiaries are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

*Chartered Accountants*

Firm's Registration No.:101248W/W-100022



**Vikash Gupta**

*Partner*

Bangalore

01 August 2024

Membership No.: 064597

UDIN:24064597BKDHQL2360

## Limited Review Report (Continued)

## Indegene Limited (formerly known as Indegene Private Limited)

## Annexure I

The unaudited consolidated financial results include financial results of the Holding Company and entities listed below:

Sr. No	Name of component	Relationship	Country of Incorporation
1	ILSL Holdings Inc.	Subsidiary	USA
2	Indegene Japan LLC	Subsidiary	Japan
3	Indegene Healthcare Mexico S DE RL DE CV	Subsidiary	Mexico
4	Indegene Ireland Limited	Subsidiary (w.e.f. 30 June 2023) Step-Subsidiary (upto 29 June 2023)	Ireland
5	Indegene Inc.	Step subsidiary	USA
6	Services Indegene Aptilon Inc.	Step subsidiary	Canada
7	DT Associates Research and Consulting Services Limited	Step subsidiary	England
8	Cult Health LLC	Step subsidiary	USA
9	Indegene Healthcare Germany GmbH	Step subsidiary	Germany
10	DT Associates Research and Consulting Inc.	Step subsidiary	USA
11	Indegene Fareast Pte. Ltd.	Step subsidiary (w.e.f. 28 December 2023) Subsidiary (upto 27 December 2023)	Singapore
12	Indegene Europe LLC	Step subsidiary (w.e.f. 27 December 2023) Subsidiary (upto 26 December 2023)	Switzerland
13	Indegene Lifesystems Consulting (Shanghai) Co. Ltd.	Step subsidiary (w.e.f. 29 February 2024) Subsidiary (upto 28 February 2024)	China
14	Indegene Healthcare UK Limited	Step subsidiary (w.e.f. 07 December 2023)	England

**Limited Review Report (Continued)**

**Indegene Limited (formerly known as Indegene Private Limited)**

Sr. No	Name of component	Relationship	Country of Incorporation
15	Trilogy Writing & Consulting GmbH	Step subsidiary (w.e.f. 22 March 2024)	Germany
16	Trilogy Writing & Consulting Limited	Step subsidiary (w.e.f. 22 March 2024)	England
17	Trilogy Writing & Consulting Inc.	Step subsidiary (w.e.f. 22 March 2024)	USA
18	Trilogy Writing & Consulting ULC	Step subsidiary (w.e.f. 22 March 2024)	Canada

V4.

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		Unaudited	Audited (Refer note 3)	Unaudited	Audited
1	<b>Income</b>				
	(a) Revenue from operations	6,765	6,730	6,075	25,896
	(b) Other income (net)	225	232	285	763
	<b>Total income</b>	<b>6,990</b>	<b>6,962</b>	<b>6,360</b>	<b>26,659</b>
2	<b>Expenses</b>				
	(a) Employee benefits expense	4,443	4,284	4,047	16,516
	(b) Finance costs	117	123	126	494
	(c) Depreciation and amortisation expense	201	185	202	761
	(d) Other expenses	1,033	1,059	1,060	4,326
	<b>Total expenses</b>	<b>5,794</b>	<b>5,651</b>	<b>5,435</b>	<b>22,097</b>
3	<b>Profit before exceptional item and tax (1-2)</b>	<b>1,196</b>	<b>1,311</b>	<b>925</b>	<b>4,562</b>
4	Exceptional items (net) (refer note 7)	-	24	-	24
5	<b>Profit before tax (3+4)</b>	<b>1,196</b>	<b>1,335</b>	<b>925</b>	<b>4,586</b>
6	<b>Tax expense</b>				
	- Current tax	352	131	175	1,255
	- Deferred tax	(33)	256	66	(36)
	<b>Total Tax Expense</b>	<b>319</b>	<b>387</b>	<b>241</b>	<b>1,219</b>
7	<b>Profit for the period / year (5-6)</b>	<b>877</b>	<b>948</b>	<b>684</b>	<b>3,367</b>
8	<b>Other Comprehensive Income (OCI), net of taxes</b>				
	<i>Items that will not be reclassified subsequently to the statement of profit or loss:</i>				
	Remeasurement of defined benefit obligation	15	(2)	1	^
	Income tax impact	(4)	1	^	^
	<i>Items that will be reclassified subsequently to profit or loss:</i>				
	Exchange differences on translating the financial statements of foreign operations	(19)	19	(20)	79
	<b>Total Other Comprehensive (Loss)/Income for the period/year (net of tax)</b>	<b>(8)</b>	<b>18</b>	<b>(19)</b>	<b>79</b>
9	<b>Total comprehensive income for the period / year (7+8)</b>	<b>869</b>	<b>966</b>	<b>665</b>	<b>3,446</b>
	<b>Profit for the period / year attributable to:</b>				
	Owners of the Parent	877	948	684	3,367
	<b>Other Comprehensive (Loss)/Income for the period / year attributable to:</b>				
	Owners of the Parent	(8)	18	(19)	79
	<b>Total comprehensive income for the period / year attributable to Owners of the Parent</b>	<b>869</b>	<b>966</b>	<b>665</b>	<b>3,446</b>
10	Paid-up equity share capital (Face value of ₹ 2 each)	479	444	443	444
11	Other equity				13,847
12	<b>Earnings per equity share (face value of ₹ 2 each)*</b>				
	(a) Basic (in ₹)	3.79	4.27	3.09	15.19
	(b) Diluted (in ₹)	3.76	4.24	3.07	15.07

\*Earnings per share is not annualised for quarter ended.

See accompanying notes to the Consolidated Financial Results



(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Consolidated Financial Results of the Group have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("the regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 01 August 2024. The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter ended 30 June 2024 and have issued an unmodified review report on the same.
3. The Consolidated Financial Results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figure in respect of the full financial year and audited the year to date figure up to 31 December 2023.
4. The Consolidated Financial Results for the quarter ended 30 June 2024, are available on the National Stock Exchange of India Limited (URL: [www.nseindia.com](http://www.nseindia.com)), the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)) and on the Company's website (URL: [www.indegene.com/investor-relations](http://www.indegene.com/investor-relations)).
5. During the quarter ended 30 June 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹2 each at an issue price of ₹452 per share, comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish quarterly results for the quarter ended 30 June 2023 in accordance with the regulations.
6. On 22 March 2024, the Group had obtained control of Trilogy Writing & Consulting GmbH ('Trilogy GmbH'), by acquiring 100% of its shares. The acquisition was consummated for a consideration of ₹1,457 which includes earnout payment of ₹489. The contingent consideration is based on the performance of Trilogy GmbH during the fiscal year beginning 01 April 2024 and ending 31 March 2025 and range of contingent consideration payable is between Nil to ₹ 1,268. The Group has concluded that the acquired set is a business.

The purchase price allocation for Trilogy GmbH is provisional and will be finalized within the measurement period, but in no event later than one year following the date of acquisition. The Group is in the process of making a final determination of the fair value of assets and liabilities, contingent consideration and useful lives of certain identified intangibles.

7. Exceptional items:

On 12 October 2022, the Group had obtained control of Cult Health LLC by acquiring 100% interest to enhance the Group's commercialization portfolio adding market development and brand strategy competencies along with patient engagement platforms. The acquisition was consummated for a consideration of ₹ 5,347. The contingent consideration is based on the performance of Cult during the fiscal year beginning 01 April 2023 and ending 31 March 2026 and range of contingent consideration payable is between ₹ Nil to ₹ 3,040. Cult Health LLC is part of Omnichannel Activation segment.

The Group carried out remeasurement of the change in fair value of contingent consideration towards earnout payout, which was measured at its fair value on acquisition and recognised a resultant gain of ₹935. Change in fair value movement of contingent consideration has been recognized as an exceptional item during the quarter and year ended 31 March 2024. Further, the Group also carried out the assessment of recoverable value of the investments made in Cult Health LLC owing to reduction in revenues from certain customers and its impact on the future cash flows. The recoverable amount of this CGU estimated to be lower than carrying value, resulting into an impairment charge of ₹911. The impairment charge had been recognized as an exceptional item during the quarter and year ended 31 March 2024.

(All amounts in ₹ millions, except share data and where otherwise stated)

8. The Segment results of the Group has been prepared in accordance with AS-108 on "Operating Segments". The Group has identified business segments (industry practice) as reportable segments. The business segments comprise: 1) Enterprise Medical Solutions, 2) Enterprise Commercial Solutions, 3) Omnichannel Activation.

Segment wise revenue and results are as follows:

Particulars	Quarter ended			Year ended
	30 June	31 March	30 June	31 March
	2024	2024	2023	2024
	Unaudited	Audited (refer note 3)	Unaudited	Audited
<b>1. Segment revenue</b>				
Enterprise Medical Solutions	1,889	1,602	1,410	6,008
Enterprise Commercial Solutions	3,749	3,927	3,672	15,287
Omnichannel Activation	823	879	664	3,191
Others*	304	322	329	1,410
<b>Total</b>	<b>6,765</b>	<b>6,730</b>	<b>6,075</b>	<b>25,896</b>
<b>2. Segment results</b>				
Enterprise Medical Solutions	441	475	349	1,679
Enterprise Commercial Solutions	869	990	775	3,627
Omnichannel Activation	88	92	(36)	256
Others*	(71)	(64)	(77)	(213)
<b>Total</b>	<b>1,327</b>	<b>1,493</b>	<b>1,011</b>	<b>5,349</b>
Unallocable expenses	(38)	(106)	(44)	(295)
Depreciation and amortisation expense	(201)	(185)	(202)	(761)
Other income (net)	225	232	286	763
Finance cost	(117)	(123)	(126)	(494)
Exceptional items	-	24	-	24
Tax expense	(319)	(387)	(241)	(1,219)
<b>Profit after Tax</b>	<b>877</b>	<b>948</b>	<b>684</b>	<b>3,367</b>

\*Others mainly comprises of consultancy and clinical business.

#### Notes on Segment information

Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker. In deciding how to allocate resources and assessing performance, the Group's chief operating decision maker is the Chief Executive Officer and Executive Director.

Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

Bengaluru  
01 August 2024



by Order of the Board of  
INDEGENE LIMITED  
(formerly INDEGENE PRIVATE LIMITED)

  
Manish Gupta  
Chief Executive Officer and Executive Director



# B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park  
Pebble Beach, B Block, 3rd Floor  
No. 13/2, off Intermediate Ring Road  
Bengaluru - 560 071, India  
Telephone: +91 80 4682 3000  
Fax: +91 80 4682 3999

## Limited Review Report on unaudited standalone financial results of Indegene Limited (formerly known as Indegene Private Limited) for the quarter ended 30 June 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Indegene Limited (formerly known as Indegene Private Limited)

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Indegene Limited (formerly known as Indegene Private Limited) (hereinafter referred to as "the Company") for the quarter ended 30 June 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2024 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the unaudited year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Vikash Gupta

Partner

Bangalore

01 August 2024

Membership No.: 064597

UDIN: 24064597BKDHQK4757

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400083

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended		Year ended	
		30 June 2024	31 March 2024	30 June 2023	31 March 2024
		Unaudited	Unaudited (Refer note 3)	Unaudited	Audited
1	<b>Income</b>				
	(a) Revenue from operations	2,586	2,725	2,525	10,456
	(b) Other income (net)	137	231	120	503
	<b>Total income</b>	<b>2,723</b>	<b>2,956</b>	<b>2,645</b>	<b>10,959</b>
2	<b>Expenses</b>				
	(a) Employee benefits expense	1,853	1,949	1,840	7,523
	(b) Finance costs	15	15	17	66
	(c) Depreciation and amortisation expense	66	76	88	311
	(d) Other expenses	338	312	309	1,253
	<b>Total expenses</b>	<b>2,272</b>	<b>2,352</b>	<b>2,254</b>	<b>9,153</b>
3	<b>Profit before tax (1-2)</b>	<b>451</b>	<b>604</b>	<b>391</b>	<b>1,806</b>
4	<b>Tax expense</b>				
	- Current tax	119	121	110	443
	- Deferred tax	6	(6)	(15)	(16)
	<b>Total tax expense</b>	<b>125</b>	<b>115</b>	<b>95</b>	<b>427</b>
5	<b>Profit for the period/year (3-4)</b>	<b>326</b>	<b>489</b>	<b>296</b>	<b>1,379</b>
6	<b>Other Comprehensive Income (OCI), net of taxes</b>				
	<i>Items that will not be reclassified subsequently to the statement of profit or loss:</i>				
	Remeasurement of defined benefit obligation	15	(2)	1	^
	Income tax impact	(4)	-	^	^
	<i>Items that will be reclassified subsequently to profit or loss:</i>				
	Exchange differences on translating the financial statements of foreign operation	(4)	(1)	-^	(1)
	<b>Total Other Comprehensive Income/(Loss) for the period/year (net of tax)</b>	<b>7</b>	<b>(3)</b>	<b>1</b>	<b>(1)</b>
7	<b>Total comprehensive income for the period/year (5+6)</b>	<b>333</b>	<b>486</b>	<b>297</b>	<b>1,378</b>
8	Paid-up equity share capital (Face value of ₹ 2 each)	479	444	443	444
9	Other equity				9,094
10	<b>Earning per equity share (face value ₹ 2 each)</b>				
	(a) Basic (in ₹)	1.41	2.20	1.34	6.22
	(b) Diluted (in ₹)	1.39	2.19	1.33	6.17

\*Earnings per share is not annualised for quarter ended.

See accompanying notes to the Standalone financial results

**Indegene Limited** (formerly Indegene Private Limited)

CIN No. U73100KA1998PLC102040

**Notes to the Statement of Standalone Financial Results for quarter ended 30 June 2024**

(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Standalone Financial Results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("the regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 01 August 2024. The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter ended 30 June 2024 and have issued an unmodified review report on the same.
3. The Standalone Financial Results include the results for the quarter ended 31 March 2024 being the balancing figure between the audited figure in respect of the full financial year and the unaudited year to date figure up to 31 December 2023, which were subject to limited review.
4. The Standalone Financial Results for the quarter ended 30 June 2024, are available on the National Stock Exchange of India Limited (URL: [www.nseindia.com](http://www.nseindia.com)), the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)) and on the Company's website (URL: [www.indegene.com/investor-relations](http://www.indegene.com/investor-relations)).
5. During the quarter ended 30 June 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹2 each at an issue price of ₹452 per share, comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish quarterly results for the quarter ended 30 June 2023 in accordance with the regulations.
6. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results.

By Order of the Board of  
**INDEGENE LIMITED**  
(formerly INDEGENE PRIVATE LIMITED)



**Manish Gupta**  
Chief Executive Officer and Executive Director

Bengaluru  
01 August 2024




Date:- July 30,2024

**The Declaration by CFO regarding audit report with unmodified opinion**

I, Suhas Prabhu, Chief Financial Officer of the Company, hereby declare, that the Company's Statutory Auditors B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181), Chartered Accountants, have submitted an unmodified opinion / unqualified opinion on the unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2024.

For Indegene Limited  
(Formerly Indegene Private Limited)



Suhas Prabhu  
Chief Financial Officer



**Registered office**

Indegene Limited (Formerly Indegene Private Limited),  
Third Floor, Aspen G-4 Block, Manyata Embassy Business  
Park (SEZ), Outer Ring Road, Nagawara,  
Bengaluru- 560 045, Karnataka, India

Phone : +91 80 4674 4567, +91 80 4644 7777  
[www.indegene.com](http://www.indegene.com)

CIN: U73100KA1998PLC102040